Journal of Neurology最新文献

{"title":"Chronic dizziness in the elderly: small vessel disease and cortical atrophy : Comment on \"Evaluation of a multimodal diagnostic algorithm for prediction of cognitive impairment in elderly patients with dizziness\", by Felfela et al. (J of Neurol https://doi.org/10.1007/s00415-024-12403-3).","authors":"Adolfo M Bronstein, Diego N Kaski, Toby J Ellmers, Qadeer Arshad, Patricia B Castro, Louisa Murdin","doi":"10.1007/s00415-024-12605-9","DOIUrl":"10.1007/s00415-024-12605-9","url":null,"abstract":"","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7321-7322"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142468004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric antigen receptor T cell (CAR-T) therapy in neurological disease.","authors":"O Gbadegesin, P Prasad, M D Willis","doi":"10.1007/s00415-024-12718-1","DOIUrl":"10.1007/s00415-024-12718-1","url":null,"abstract":"","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7358-7360"},"PeriodicalIF":4.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacotherapy of motor symptoms in early and mid-stage Parkinson's disease: guideline \"Parkinson's disease\" of the German Society of Neurology.","authors":"Matthias Höllerhage, Jos Becktepe, Joseph Classen, Günther Deuschl, Georg Ebersbach, Franziska Hopfner, Paul Lingor, Matthias Löhle, Sylvia Maaß, Monika Pötter-Nerger, Per Odin, Dirk Woitalla, Claudia Trenkwalder, Günter U Höglinger","doi":"10.1007/s00415-024-12632-6","DOIUrl":"10.1007/s00415-024-12632-6","url":null,"abstract":"<p><strong>Background and objective: </strong>There are multiple pharmacological treatment options for motor symptoms of Parkinson's disease (PD). These comprise multiple drug classes which are approved for the condition, including levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors, NMDA-receptor antagonists, anticholinergics, and others. Some of the drugs are approved for monotherapy and combination therapy while others are only approved as adjunctive therapy to levodopa. Furthermore, treatment for special treatment situations, e.g., rescue medication for off-phases, for tremor, treatment during pregnancy and breast feeding is discussed and recommendations are given with further details.</p><p><strong>Methods: </strong>The recommendations were based on systematic literature reviews, drafted by expert teams, consented in online polls followed by online consensus meetings of the whole German Parkinson's Guideline Group, and publicly released in November 2023.</p><p><strong>Results: </strong>In the new S2k (i.e., consensus-based) guidelines, the pharmacotherapy of the motor symptoms of PD is discussed in five chapters. These comprise \"Parkinson medication\", \"Initial monotherapy\", \"Early combination therapy\", \"Fluctuations and dyskinesia\", and \"Parkinsonian tremor\". Furthermore, there is a chapter for special treatment situations, including perioperative management, freezing of gait, and pregnancy and breastfeeding.</p><p><strong>Conclusion: </strong>The recommendations for the pharmacotherapy of motor symptoms of PD have been updated. Newly available drugs have been added, while other drugs (e.g., ergoline dopamine agonists, anticholinergics, budipine) have been removed from the recommendations.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7071-7101"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurofilament light chain as a diagnostic and prognostic biomarker in Guillain-Barré syndrome.","authors":"Brynhildur Hafsteinsdóttir, Helen Farman, Nina Lagerström, Henrik Zetterberg, Oluf Andersen, Lenka Novakova, Bengt Nellgård, Hans Rosén, Clas Malmeström, Igal Rosenstein, Jan Lycke, Markus Axelsson","doi":"10.1007/s00415-024-12679-5","DOIUrl":"10.1007/s00415-024-12679-5","url":null,"abstract":"<p><strong>Background: </strong>Elevated neurofilament light chain (NfL) levels are associated with worse prognosis in Guillain-Barré syndrome (GBS). Our objectives were to determine the utility of serum NfL (sNfL), cerebrospinal fluid (CSF)/serum NfL ratio and NfL index as prognostic and diagnostic biomarkers for GBS.</p><p><strong>Methods: </strong>We measured NfL in serum and/or CSF obtained from 96 GBS patients between 1989 and 2014 in western Sweden. The sNfL Z-scores, NfL ratios and NfL indices were calculated. Outcome was determined with the GBS disability scale (GBSDS) at 3 and 12 months. NfL parameters in GBS were compared with healthy controls (HC), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS).</p><p><strong>Results: </strong>The sNfL Z-score was higher for GBSDS > 2 at 3 months (median [IQR], 3.5 ng/L [3.2-4.0], vs 2.6 [1.7-3.4], p = 0.008) and at 12 months (3.6 ng/L [3.5-3.8] vs 2.6 [1.8-3.5], p = 0.049). NfL ratio and index were not associated with outcome. The area under the curve (AUC) for sNfL Z-score was 0.76 (95% CI 0.58-0.93, p < 0.0001) for GBSDS > 2 at 3 months. NfL ratio and index were lower in GBS than HC, MS, and ALS. The AUC for the NfL ratio was 0.66 (95% CI 0.55-0.78, p = 0.0018) and for the NfL index 0.86 (95% CI 0.78-0.93, p < 0.0001).</p><p><strong>Discussion: </strong>Our results confirm sNfL as prognostic biomarker for GBS and the precision was improved using the age-adjusted sNfL Z score. NfL index and Qalb are potential diagnostic biomarkers for GBS.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7282-7293"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validation of the International REM Sleep Behavior Disorder Study Group Symptoms Severity Scale (IRBD-SSS): a new tool to assess RBD clinical severity.","authors":"Maria Livia Fantini, Ronald B Postuma, Monica Puligheddu, Isabelle Rieu, Enguerrand Venel, Michela Figorilli, Valerie Cochen-DeCock, Laurene Leclair-Visonneau, Dario Arnaldi, Pietro Mattioli, Laure Peter-Derex, François Ricordeau, Michele Terzaghi, Isabelle Arnulf, Ambra Stefani, Aleksandar Videnovic, Coline Chirol, Bruno Pereira","doi":"10.1007/s00415-024-12702-9","DOIUrl":"10.1007/s00415-024-12702-9","url":null,"abstract":"<p><strong>Background: </strong>Currently, no standard scale has been validated to assess overall severity of RBD symptoms in the home environment. We aimed to evaluate the psychometric properties of the International RBD Severity Scale (IRBD-SSS), a new tool designed by the International RBD Study Group.</p><p><strong>Methods: </strong>Two versions of the IRBD-SSS were created, one for the patient (IRBD-SSS-PT) and another for the bedpartner (IRBD-SSS-BP), both consisting of 3 components, namely vocalizations, body movements and injury, with a fourth component (patient version only) evaluating dream content. To score each dimension, the frequency and severity/impact of behaviors during the previous month are multiplied. Psychometric properties of the IRBD-SSS were assessed, including reproducibility.</p><p><strong>Results: </strong>A total of 188 subjects including n = 132 RBD patients (n = 94 isolated RBD and n = 38 symptomatic RBD) and n = 52 bedpartners were enrolled from eight Sleep centers across France and Italy. Participants completed the scale at baseline and after one week. Acceptability of the scale was excellent in patients (97%) and bedpartners (98%). Internal consistency was acceptable for IRBD-SSS-PT (Cronbach α = 0.75) while slightly low for IRBD-SSS-BP (Cronbach α = 0.49). Concurrent validity was good for both patient (r = 0.70;p < 0.001, see Figure) and bedpartner (r = 0.69;p < 0.001) IRBD-SSS. Reproducibility was high for IRBD-SSS-PT (Lin's coefficient of agreement = 0.85 [0.81;0.90]) and good for the IRBD-SSS-BP (0.79 [0.68;0.90] (p < 0.001).</p><p><strong>Conclusions: </strong>Both the patient and bedpartner versions of the IRBD-SSS showed excellent acceptability, acceptable internal consistency, good external validity and high reproducibility. IRBD-SSS is a useful tool to test the severity of RBD symptoms in clinical settings and clinical trials.</p><p><strong>Trial registration: </strong>NCT04071899.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7264-7271"},"PeriodicalIF":4.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142348506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cognitive performance from childhood to old age and intergenerational correlations in the multigenerational Young Finns Study.","authors":"Marja A Heiskanen, Jaakko Nevalainen, Katja Pahkala, Markus Juonala, Nina Hutri, Mika Kähönen, Eero Jokinen, Tomi P Laitinen, Päivi Tossavainen, Leena Taittonen, Jorma S A Viikari, Olli T Raitakari, Suvi P Rovio","doi":"10.1007/s00415-024-12693-7","DOIUrl":"10.1007/s00415-024-12693-7","url":null,"abstract":"<p><strong>Background: </strong>Cognitive performance changes during the lifespan, but the information is gathered from studies on separate age cohorts. Computerized neurocognitive testing enables efficient and similar assessments for all ages. We investigated (i) the effect of age at different stages of life and (ii) intergenerational correlations across cognitive domains in the multigenerational Young Finns Study.</p><p><strong>Methods: </strong>Participants in three familiarly related generations (n = 6486, aged 7-92 years) performed the Cambridge Neuropsychological Test Automated Battery (CANTAB). Overall cognitive performance and domains representing learning and memory, working memory, information processing, and reaction time were extracted by common principal component analysis from the cognitive data with several age groups. Linear models were used to study the association of age, sex, and education with overall cognitive performance and in the cognitive domains. Age-adjusted intergenerational correlations were calculated.</p><p><strong>Results: </strong>Learning and memory peaked earlier during the lifespan compared to working memory and information processing, and the rate of decline toward old age differed by domain. Weak intergenerational correlations existed between two consecutive generations but were nonsignificant between grandparents and grandchildren. There was no systematic sex-specific transmission in any cognitive domain.</p><p><strong>Conclusion: </strong>This study describes the natural course of cognitive performance across the lifespan and proves that cognitive performance changes differently across cognitive domains with weak intergenerational transmission.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7294-7308"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A frugal suggestion from a functional neurosurgeon to the german guidelines on treatment of the \"DBS withdrawal syndrome\".","authors":"Marwan Hariz","doi":"10.1007/s00415-024-12713-6","DOIUrl":"10.1007/s00415-024-12713-6","url":null,"abstract":"","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7323-7324"},"PeriodicalIF":4.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142348497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arthur Edward Durham (1834-1895).","authors":"Kariem Elhadd, Andrew J Larner","doi":"10.1007/s00415-024-12646-0","DOIUrl":"10.1007/s00415-024-12646-0","url":null,"abstract":"","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7361-7362"},"PeriodicalIF":4.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142073101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson's disease: new spotlights on diagnostic procedures and non-pharmacological interventions.","authors":"Elke Kalbe, Ann-Kristin Folkerts, Karsten Witt, Carsten Buhmann, Inga Liepelt-Scarfone","doi":"10.1007/s00415-024-12503-0","DOIUrl":"10.1007/s00415-024-12503-0","url":null,"abstract":"<p><strong>Background and objective: </strong>Cognitive impairment and dementia as well as affective disorders are common and debilitating syndromes that develop in people with Parkinson's disease (PwPD). The authors summarized recommendations for the 2023 updated German guidelines on \"Parkinson's disease\" from the German Neurological Society (DGN), focusing on the diagnosis and treatment of these disorders.</p><p><strong>Methods: </strong>The recommendations were based on literature reviews, other relevant guidelines, and expert opinions.</p><p><strong>Results: </strong>Measurements to assess cognitive and affective states were reviewed for psychometric properties, use in routine clinical practice, and availability in German. To improve mild cognitive impairment, cognitive training and physical aerobic training are recommended. To treat Parkinson's disease (PD)-related dementia, cognitive stimulation (as a non-pharmacological intervention) and acetylcholinesterase inhibitors (AChEIs, i.e., rivastigmine) are recommended. Cognitive behavioral therapy is recommended to treat depression, anxiety, and fear of progression. Physical interventions are recommended to treat depression, fatigue, and apathy. Optimized dopaminergic treatment is the first-line pharmacological strategy recommended to manage depression, apathy, anhedonia, fatigue, and mood swings. Major depression can be additionally treated using venlafaxine or desipramine, while moderate depression can be treated pharmacologically according to its clinical phenotype (psychomotor retardation or agitation) and comorbidities (e.g., sleep disturbances, pain). Venlafaxine and nortriptyline can be used to treat anhedonia, while citalopram can be used for anxiety.</p><p><strong>Conclusions: </strong>In addition to the updated pharmacological treatment options, new insights into recommendations for standardized diagnostics and non-pharmacological interventions were provided for the German health care system. However, more studies are needed to explore the full potential of non-pharmacological interventions to treat and prevent cognitive impairment and affective disorders.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7330-7357"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561078/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: eHealth tools to assess the neurological function for research, in absence of the neurologist - a systematic review, part I (software).","authors":"Vasco Ribeiro Ferreira, Esther Metting, Joshua Schauble, Hamed Seddighi, Lise Beumeler, Valentina Gallo","doi":"10.1007/s00415-024-12558-z","DOIUrl":"10.1007/s00415-024-12558-z","url":null,"abstract":"","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":" ","pages":"7376"},"PeriodicalIF":5.4,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11560976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142289399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}